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Radiation exposure from medical imaging is one of the
largest sources of radiation exposure to the general popu-
lation, second after natural background exposures.
1 In
2008 there were 46 million medical and dental examinations
performed in the UK. The mean annual dose per person
from this source increased by 23% between 1997 and
2008,
2 primarily due to the doubling in the number of com-
puted tomography (CT) scans over that period to 3.4 million
per year. The average radiation dose from a CT scan is typi-
cally ten times higher than a conventional diagnostic X-ray
(0.1–10 milli-Sievert [mSv] effective dose). There is
concern about the potential risk of cancer from the increas-
ing levels of medical radiation exposure in the UK and other
developed countries. Furthermore, several types of CT scans,
including lung CT, coronary artery calciﬁcation CT and CT
colonography, have been proposed as new screening tools.
The decision to expose large numbers of asymptomatic indi-
viduals to repeated radiation exposure raises legitimate
concerns.
The Health Protection Agency’s Advisory Group on
Ionising Radiation commissioned a Sub-group on Solid
Cancer Risk to write a report on cancer risks from radiation
exposure to the UK population.
3 The aims of the report were
1) to review information on the risk of solid cancers from
exposure to ionising radiation, such as breast and lung
cancer, but not on cancers such as lymphoma or leukaemia
as these were reviewed in a separate report,
4 2) to derive risk
estimates applicable to the UK population with a quantitat-
ive assessment of the effects of typical radiation exposures
the public may experience. These risk estimates were then
used to estimate the risk of radiation-related cancer for
several types of screening examinations. The results of this
exercise are summarized here along with a brief summary
of the broader report.
There is a considerable amount of information on the risks
of solid cancer from various epidemiological studies of
radiation-exposed populations. The committee reviewed
the available data to assess whether there is evidence of an
association between cancers at speciﬁc sites and ionising
radiation exposure and whether the association was likely
to be causal. Assessment of causality was based on evidence
of a dose-response relationship, the magnitude of the rela-
tive risk and the likelihood of uncontrolled confounding.
For many, but not all solid cancers, the committee con-
cluded that there was epidemiological evidence of an associ-
ation with ionising radiation exposure and in most instances
this association was judged to be causal; speciﬁcally, for
cancers of the oesophagus, stomach, colon, rectum, liver,
lung, bone, non-melanoma skin, breast (female), bladder
and thyroid, together with brain and other central nervous
system tumours. For cancers of the salivary glands and
ovary, the association was judged to be probably causal.
For some cancers it is unclear whether they are caused by
ionising radiation exposure; these include cancers of the
pancreas, connective tissue, melanoma of skin, uterine
cervix, body of uterus, prostate and testis.
The lifetime risk of radiation-induced solid cancer was
estimated for the UK population. These estimates were
based on risk models developed using cancer incidence
and mortality collected from the Japanese atomic bomb sur-
vivors Life Span Study.
5 This study remains the basis for
much risk assessment work due to its large size, long-term
follow-up, and the wide variety of doses and range in age
at exposure. However, data from studies of medically-
exposed groups sometimes help to provide more pertinent
estimates, particularly for rare cancers such as thyroid,
bone and non-melanoma skin, and for breast cancer in
females where baseline rates differ considerably between
Japan and Western countries.
To conduct the calculations organ-speciﬁc radiation doses
were estimated for each screening test from survey infor-
mation
6 or screening protocols
7–9and these were multiplied
by the estimated lifetime risk of radiation-related cancer for
each organ, for the relevant age at exposure and sex.
3 The
total cancer risk was then calculated by summing across all
the exposed organs. There is debate about the most appro-
priate method to transfer risk models from the Japanese to
other populations. The approach used in the report was to
estimate risks using two models: 1) an excess relative risk
model that assumes that the radiation exposure acts multi-
plicatively on the underlying cancer incidence rates and 2)
an absolute excess risk model that assumes that the radiation
exposure acts additively on the underlying rates. Results
are presented from both models and to some extent these
represent the range of likely risks. If there was a supra-
multiplicative or sub-additive interaction then risks could
lie outside this range but to date there is little evidence for
such effects.
The risk estimates for repeated screening are summarized
in Table 1. The smallest risks are for repeated mammography
(0.3–0.6 cancers per 1000 women screened every three
years from age 47–73). This is due to the relatively low radi-
ation dose per mammographic X-ray and the fact that it only
results in a measurable dose to one organ, the breast. The
highest risk estimates were for lung CT screening in
females (2.9–8.0 per 1000), primarily because annual
screening was assumed due to the short pre-clinical
detection period for lung cancer screening with CT.
10
If individuals underwent all of these screening tests routi-
nely then over the lifetime there would be an estimated
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6–13 cancers per 1000 women screened. Risk estimates
are higher for women than for men whenever there is
breast exposure (lung CT screening and coronary artery cal-
ciﬁcation screening).
Beneﬁts, where established, should outweigh the small
risk of radiation-related cancer. For example, a decade of
post-menopausal mammographic screening is estimated to
prevent about one breast cancer death per 400 women
screened.
11 The ﬁrst randomized trial of lung CT screening
found that three annual screens reduced lung cancer mor-
tality by 20% in heavy smokers,
12 equivalent to about
three lung cancer deaths prevented per 1000 screened. An
important caveat though is that even if the beneﬁts do out-
weigh the radiation risks at older screening ages this may not
be the case for screening at younger ages because the radi-
ation risks are higher but the absolute beneﬁts are lower.
The balance may also differ for higher risk sub-groups
such as smokers or women with a family history of breast
cancer. Situations such as these require detailed evaluation.
The value of CT coronary artery calciﬁcation screening and
CT colonography has not been established directly. Even
small risks, therefore, could outweigh beneﬁts.
The dose estimates for mammographic screening were
based on national dose survey data from the UK.
6 For the
other screening examinations the doses were estimated
using published screening protocols.
7–9 These have been
developed speciﬁcally to ensure low doses whilst maintain-
ing the necessary image quality. It is important that proto-
cols are optimized in this way and that quality control
programmes are in place to monitor doses.
The use of ionising radiation in medical screening has
increased in recent years. This raises legitimate health con-
cerns. It is important to consider the potential risk of
radiation-related cancer from screening and diagnostic
imaging when setting public health recommendations for
their use.
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Table1 Estimates of the total lifetime risk of radiation-related cancer for various screening scenarios. The risks are expressed as the
number of cancer cases expected in 1000 people
Screening test, frequency and age at exposure
Model
type Sex
Mammography
every 3 years
age 47–73
CT assessment of coronary
artery calciﬁcation every
5 years age 45–70 males,
age 55–70 females
CT colonography
every 5 years age
55–70
Lung CT
every year
age 50–70
Total risk from
all screening
tests
ERR Males n.a. 1.4 2.6 3.0 7.0
Females 0.6 2.3 2.0 8.0 12.8
EAR Males n.a. 0.6 2.7 1.4 4.7
Females 0.3 0.7 1.9 2.9 5.8
n.a. – not applicable
ERR – excess relative risk
EAR – excess absolute risk
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